Arkolith/Insider Trading/EVLO/Form 4

Gill Simba

President & CEO, DirectorEvelo Biosciences, Inc. (EVLO) · full profile →Form 4 · filed Sep 29, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$8K
Net Open-Market Flow
-$8K
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 28, 2023Sell(S)2K$3.94$8K17K
Sep 27, 2023Option exercise(M)15K——19K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 27, 2023Option exercise(M)15K—$045K
Sep 27, 2023Grant(A)60K—$060K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001694665-23-000160) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML